DMK Pharmaceuticals's EBIT per Share for the
three
months ended in Sep. 2023 was $-0.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.95.
During the past 3 years, the average EBIT per Share Growth Rate was 32.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 31.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for DMK Pharmaceuticals's EBIT per Share or its related term are showing as below:
DMKPQ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.1 Med: 26.3 Max: 78.2
Current: 32.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of DMK Pharmaceuticals was 78.20% per year. The lowest was -38.10% per year. And the median was 26.30% per year.
DMKPQ's 3-Year EBIT Growth Rate is ranked better than 79.14% of 863
companies
in the Drug Manufacturers industry
Industry Median: 7.3
vs DMKPQ: 32.60
DMK Pharmaceuticals EBIT per Share Historical Data
The historical data trend for DMK Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals (OTCPK:DMKPQ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
DMK Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 